(Q36695189)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

TP53 status determines clinical significance of ERBB2 expression in ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

Erb-b2 receptor tyrosine kinase 2

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Radosław Mądry

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Janina Markowska

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Izabella Rzepka-Górska

12

object named as

I Rzepka-Górska

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

J Plisiecka-Hałasa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J Bar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

E Kraszewska

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

I Ziółkowska

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A Timorek

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J Stelmachów

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J Emerich

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

M Jedryka

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A Płuzańska

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

K Urbański

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J Zieliński

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

language of work or name

English

0 references

publication date

1 November 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

91

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

1916-1923

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602238

5 January 2020

exact match

0 references

cites work

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Mechanism of action of anti-HER2 monoclonal antibodies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Salvage chemotherapy for epithelial ovarian carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Reporting results of cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2409772

Nonparametric Estimation from Incomplete Observations

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6602238

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer

21 January 2018

1 reference

12 December 2020

HER-2 breast assay, linked to Herceptin, wins FDA's okay

1 reference

12 December 2020

The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells

1 reference

12 December 2020

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

12 December 2020

Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis

1 reference

12 December 2020

c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis

1 reference

12 December 2020

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

12 December 2020

Role of p53 in HER2-induced proliferation or apoptosis

1 reference

12 December 2020

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

12 December 2020

Prognostic significance of c-erB-2 mRNA in ovarian carcinoma

1 reference

12 December 2020

Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

1 reference

12 December 2020

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

1 reference

12 December 2020

NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms

1 reference

12 December 2020

Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer

1 reference

12 December 2020

Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression

1 reference

12 December 2020

Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer

1 reference

12 December 2020

Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma

1 reference

12 December 2020

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15545967%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

PubMed publication ID

15545967

1 reference